Martínez-Martínez L, Joyanes P, Suárez A I, Perea E J
Department of Microbiology, School of Medicine and University Hospital Virgen Macarena, Seville, Spain.
Antimicrob Agents Chemother. 2001 Aug;45(8):2390-2. doi: 10.1128/AAC.45.8.2390-2392.2001.
The in vitro activities of gemifloxacin, ciprofloxacin, ampicillin, doxycycline, gentamicin, and vancomycin were evaluated against 15 Listeria monocytogenes strains and 205 coryneform bacteria isolated from clinical samples. The percentages of strains inhibited by gemifloxacin at 0.5 microg/ml were 100% (L. monocytogenes), 93.3% (Brevibacterium spp.), 90% (Corynebacterium minutissimum), 42.5% (Corynebacterium amycolatum), 20% (Corynebacterium striatum), 12.5% (Corynebacterium jeikeium), and 10% (Corynebacterium urealyticum). One hundred percent of the L. monocytogenes strains were inhibited by 0.25 microg of gemifloxacin per ml, whereas 0% of the strains were inhibited by 0.25 microg of ciprofloxacin per ml. Vancomycin at 2 microg/ml inhibited all strains. Doxycycline and gentamicin at 4 microg/ml inhibited 94 and 49% of the strains, respectively, while ampicillin at 0.5, 2, and 8 microg/ml inhibited 24, 61, and 66% of the strains, respectively. It is concluded that gemifloxacin shows good in vitro activity against L. monocytogenes and coryneform bacteria except C. jeikeium and C. urealyticum.
对吉米沙星、环丙沙星、氨苄西林、多西环素、庆大霉素和万古霉素针对从临床样本中分离出的15株单核细胞增生李斯特菌菌株和205株棒状杆菌的体外活性进行了评估。吉米沙星在0.5微克/毫升浓度下抑制菌株的百分比分别为:100%(单核细胞增生李斯特菌)、93.3%(短棒杆菌属)、90%(极小棒状杆菌)、42.5%(无枝菌酸棒状杆菌)、20%(纹带棒状杆菌)、12.5%(杰氏棒状杆菌)和10%(解脲棒状杆菌)。每毫升0.25微克的吉米沙星可抑制100%的单核细胞增生李斯特菌菌株,而每毫升0.25微克的环丙沙星对菌株的抑制率为0%。2微克/毫升的万古霉素可抑制所有菌株。4微克/毫升的多西环素和庆大霉素分别抑制94%和49%的菌株,而0.5、2和8微克/毫升的氨苄西林分别抑制24%、61%和66%的菌株。结论是,吉米沙星对单核细胞增生李斯特菌和除杰氏棒状杆菌和解脲棒状杆菌之外的棒状杆菌显示出良好的体外活性。